What the Research Is Saying
A new clinical analysis published in Psychiatric Times in April 2026 takes aim at a persistent problem in psychiatry: patients with treatment-resistant depression (TRD) are often kept too long on modestly effective treatments when stronger, better-evidenced options exist. The piece focuses on optimizing the deployment of what researchers call "more efficacious" interventions — a category that includes ketamine and esketamine (Spravato), alongside other advanced options like monoamine oxidase inhibitors (MAOIs) and electroconvulsive therapy (ECT).
The framing here is important. This isn't a study announcing a new drug or a breakthrough mechanism. It's a clinical practice piece, the kind that reflects a growing consensus among psychiatric specialists: the pipeline of effective TRD treatments already exists — the problem is how and when they get used. Too often, patients cycle through a long sequence of standard antidepressants with diminishing returns before any of these higher-efficacy options are seriously considered.
For patients and families navigating TRD, this distinction matters enormously. The question isn't just what works — it's at what point in treatment should it be offered.
Where Ketamine and Esketamine Fit In
Ketamine-based therapies occupy a notable place in this clinical conversation. IV ketamine and its FDA-approved nasal spray derivative esketamine (Spravato) have accumulated a substantial evidence base for rapid antidepressant effects, particularly for patients who have not responded to multiple prior treatments. The speed of response — often within hours to days rather than weeks — makes them especially relevant for patients who are actively struggling or at elevated risk.
The Psychiatric Times analysis reflects a broader shift in how leading clinicians are thinking about sequencing. Rather than reserving ketamine for a last resort after exhausting a long list of alternatives, some experts now advocate for moving to higher-efficacy options earlier in the treatment pathway, particularly when there are clear indicators of severity: persistent suicidal ideation, significant functional impairment, or a history showing repeated non-response.
This doesn't mean ketamine is right for everyone, or that earlier use is universally endorsed — the field still has meaningful debates about long-term protocols, maintenance dosing, and which patient profiles benefit most. But the directional trend in expert opinion is toward earlier consideration, not later.
It's also worth noting what "more efficacious" means in practice. These treatments tend to show higher response rates in TRD populations, but they also come with more complex administration requirements, monitoring needs, and — in the case of ketamine — a currently fragmented and sometimes expensive access landscape. Efficacy and accessibility are not the same thing, and families should weigh both.
Evidence Quality: What We're Working With
Clinical practice articles in journals like Psychiatric Times draw on existing literature rather than presenting new trial data. That means the strength of the underlying claims depends on the quality of the studies being synthesized. For ketamine and esketamine specifically, the evidence base is reasonably robust for short-term response in TRD — multiple randomized controlled trials and extensive real-world data support their use. The weaker areas are longer-term outcomes, optimal maintenance schedules, and head-to-head comparisons with other high-efficacy interventions like ECT.
Readers should approach expert consensus pieces as reflecting the current best judgment of experienced clinicians, not as definitive proof. That said, when specialists who treat TRD regularly are converging on a view — in this case, that waiting too long to offer effective treatments causes unnecessary harm — that's clinically meaningful even without a new landmark trial behind it.
Key Takeaway for Patients and Families
If you or someone you love has tried two or more antidepressants without adequate relief, you may already qualify as treatment-resistant — and the clinical conversation is increasingly clear that waiting longer before exploring ketamine, esketamine, or other higher-efficacy options may not be in your best interest. This doesn't mean these treatments are guaranteed to work or are free of considerations, but it does mean they deserve a serious discussion with your prescriber sooner rather than later. If your current provider isn't raising these options, it may be worth seeking a consultation with a psychiatrist who specializes in TRD.
Practical Implications for Your Treatment Search
For anyone actively evaluating ketamine therapy, a few things are worth keeping in mind as you process this kind of expert guidance:
Ask about sequencing, not just eligibility. The right question isn't only "am I a candidate for ketamine?" but "given where I am in my treatment history, is this the right time to try it?" A good provider will be able to explain where ketamine or esketamine fits relative to your specific history.
Understand the access landscape. IV ketamine is administered off-label in clinic settings with widely varying protocols and costs. Esketamine (Spravato) is FDA-approved for TRD and administered in certified healthcare settings, but insurance coverage varies and prior authorization requirements can be burdensome. Neither is universally accessible, which means advocacy and navigation are often part of the process.
Look for providers who think in terms of treatment sequencing. The core message from pieces like this one is that good TRD care requires strategic thinking about when to escalate — not just a menu of available options. Providers who are familiar with current TRD guidelines and actively engaged with the evidence base are better positioned to help you make these decisions.
The original article is available via Psychiatric Times.
Share